ANL 10.96 Decreased By ▼ -0.16 (-1.44%)
ASC 10.05 Increased By ▲ 0.07 (0.7%)
ASL 12.05 Increased By ▲ 0.20 (1.69%)
AVN 71.10 Decreased By ▼ -0.14 (-0.2%)
BOP 6.00 Increased By ▲ 0.05 (0.84%)
CNERGY 5.27 No Change ▼ 0.00 (0%)
FFL 7.15 Increased By ▲ 0.45 (6.72%)
FNEL 6.15 Increased By ▲ 0.05 (0.82%)
GGGL 11.75 Decreased By ▼ -0.11 (-0.93%)
GGL 15.85 Decreased By ▼ -0.07 (-0.44%)
GTECH 9.30 Decreased By ▼ -0.05 (-0.53%)
HUMNL 6.61 Increased By ▲ 0.05 (0.76%)
KEL 2.55 Decreased By ▼ -0.03 (-1.16%)
KOSM 3.06 No Change ▼ 0.00 (0%)
MLCF 28.60 Decreased By ▼ -0.10 (-0.35%)
PACE 2.98 Decreased By ▼ -0.01 (-0.33%)
PIBTL 6.04 Decreased By ▼ -0.05 (-0.82%)
PRL 15.66 Increased By ▲ 0.61 (4.05%)
PTC 7.30 Increased By ▲ 0.13 (1.81%)
SILK 1.31 Increased By ▲ 0.07 (5.65%)
SNGP 26.50 Increased By ▲ 0.35 (1.34%)
TELE 10.82 Decreased By ▼ -0.13 (-1.19%)
TPL 9.03 Decreased By ▼ -0.02 (-0.22%)
TPLP 15.85 Decreased By ▼ -0.07 (-0.44%)
TREET 29.90 No Change ▼ 0.00 (0%)
TRG 75.70 Decreased By ▼ -1.30 (-1.69%)
UNITY 22.42 Decreased By ▼ -0.03 (-0.13%)
WAVES 13.50 Increased By ▲ 0.55 (4.25%)
WTL 1.62 Increased By ▲ 0.07 (4.52%)
YOUW 5.02 Decreased By ▼ -0.02 (-0.4%)
BR100 4,281 Increased By 8.1 (0.19%)
BR30 14,910 Increased By 12.9 (0.09%)
KSE100 43,101 Increased By 117.3 (0.27%)
KSE30 16,367 Increased By 17 (0.1%)
Business & Finance

Bayer aims to help CureVac with COVID-19 vaccine output, says CEO

  • Bayer agreed this month to help fellow German company CureVac with development of its COVID-19 vaccine candidate.
17 Jan, 2021

BERLIN: German pharmaceutical giant Bayer is examining whether it can help CureVac to produce its experimental COVID-19 vaccine, its chief executive was quoted as saying on Sunday.

Though inoculation campaigns have started around the world using various COVID-19 vaccines, many countries say their ability to get shots into arms is being limited by lower than expected supplies owing to a shortage of production.

"We are prepared to pull out all the stops for this," Werner Baumann told the Welt am Sonntag newspaper.

"This is not primarily about financial considerations but about making the vaccine available as quickly as possible."

Bayer agreed this month to help fellow German company CureVac with development of its COVID-19 vaccine candidate, which is in late-stage clinical trials and has not yet been approved.

Baumann said the drugmaker was "intensively examining" whether to expand its co-operation to include manufacturing the vaccine for CureVac.

"With our production network in Germany and the USA and the corresponding lead time, we would in principle be in a position to produce vaccine in larger quantities," he said.

On Friday U.S. drugmaker Pfizer said there would be a temporary slowdown of shipments of the vaccine it developed with German partner BioNTech, citing changes in manufacturing processes to boost output.

Comments

Comments are closed.